Skip to main content
. 2023 Oct 1;37(19-20):929–943. doi: 10.1101/gad.351084.123

Figure 3.

Figure 3.

ATRi reduces growth of MMR-d tumors in vivo. (A) CT26 and CT26 Mlh1 KO (clone #13) xenograft growth with or without treatment of 50 mg/kg ATRi (AZD6738) by oral gavage every 2 d after tumor size reached 70–100 mm3. (B) Curves for overall survival for mice bearing CT26 or CT26 Mhl1 KO tumors with or without treatment of 50 mg/kg ATRi (AZD6738) by oral gavage every 2 d. (C) Images for CT26 and CT26 Mlh1 KO tumors from the indicated mouse groups. (D) B16 and B16 Mlh1 KO (clone #4) xenograft growth with or without treatment of 50 mg/kg ATRi (AZD6738) by oral gavage every 2 d after tumor size reached 70–100 mm3. (E) CT26 Mlh1 KO (clone #13) xenograft growth after depletion of CD8+ T cells by injection of anti-CD8 antibody every 3–4 d for the duration of the experiment starting 1 d before tumor implantation. Mice were treated with or without 50 mg/kg ATRi (AZD6738) by oral gavage every 2 d after tumor size reached 70–100 mm3. (F) The percentage of inhibition of tumor growth by ATRi was quantified in the presence or absence of CD8+ T cells and after 6–12 d of ATRi treatment. Mice were treated with 50 mg/kg ATRi (AZD6738) as in A.